Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
162.81B
Market cap162.81B
Price-Earnings ratio
37.69
Price-Earnings ratio37.69
Dividend yield
6.04%
Dividend yield6.04%
Average volume
35.60M
Average volume35.60M
High today
$29.09
High today$29.09
Low today
$28.46
Low today$28.46
Open price
$28.82
Open price$28.82
Volume
42.49M
Volume42.49M
52 Week high
$29.09
52 Week high$29.09
52 Week low
$23.58
52 Week low$23.58

Stock Snapshot

The current Pfizer(PFE) stock price is $28.60, with a market capitalization of 162.81B. The stock trades at a price-to-earnings (P/E) ratio of 37.69 and offers a dividend yield of 6.04%.

On 2026-09-01, Pfizer(PFE) stock traded between a low of $28.46 and a high of $29.09. Shares are currently priced at $28.60, which is +0.5% above the low and -1.7% below the high.

The Pfizer(PFE)'s current trading volume is 42.49M, compared to an average daily volume of 35.6M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.09 and a 52-week low of $23.58.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.09 and a 52-week low of $23.58.

PFE News

24/7 Wall St. 11h
CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here's Why Rivian's Didn't.

Investing CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here’s Why Rivian’s Didn’t. Three blue-chip CFO swaps touched off double-digit stock ra...

CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here's Why Rivian's Didn't.
Simply Wall St 1d
Did Targeted XFG COVID Shots Just Recenter Pfizer's Post‑Pandemic Investment Narrative?

Pfizer and BioNTech previously received FDA approval for their 2026–2027 COMIRNATY XFG mRNA COVID-19 vaccine, tailored to the XFG variant, for adults 65+ and hi...

Did Targeted XFG COVID Shots Just Recenter Pfizer's Post‑Pandemic Investment Narrative?
24/7 Wall St. 1d
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't

Investing Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t Pfizer and Starbucks both raised their outlooks this summer, but a louder recover...

Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

TipRanks 3d
Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer is quietly reshaping its pipeline, unveiling...

TipRanks 4d
Pfizer Extends Tucatinib Access With New Continuation Study: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is launching a new continuation study for tucatinib that focuses on patients...

TipRanks 4d
Pfizer’s Xalkori Lung Cancer Study Update: What Investors Need to Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a post‑marketing drug use study called “XALKORI ROS1+NSCLC D...

24/7 Wall St. 4d
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

Investing BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat A single trial readout is reshuffling the mRNA vacci...

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
Seeking Alpha 5d
Pfizer-backed Priovant wins FDA approval for lead asset

Priovant Therapeutics, a company backed by Pfizer (PFE) and Roivant Sciences (ROIV), has received FDA approval for its lead asset, Lisraya (brepocitinib), for d...

Pfizer-backed Priovant wins FDA approval for lead asset
24/7 Wall St. 5d
Wall Street Is Sleeping on These 3 Ultra-High-Yield Dividend Stocks

Investing Wall Street Is Sleeping on These 3 Ultra-High-Yield Dividend Stocks Three famous dividend names trade well below their five-year highs while their CEO...

Wall Street Is Sleeping on These 3 Ultra-High-Yield Dividend Stocks
TipRanks 5d
Pfizer’s Korean Vyndamax Study Update: What It Means for ATTR-CM Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is reporting new data from its Korean post-marketing study of Vyndamax capsul...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.